Contact this trialFirst, we need to learn more about you.
Janus Kinase (JAK) Inhibitor
Cellular Therapy + Ruxolitinib for Graft-versus-Host Disease
Recruiting1 awardPhase < 1
Houston, Texas
This trial is testing whether adding cord blood-derived mesenchymal stromal cells to ruxolitinib can help treat patients with acute graft versus host disease that has not responded to steroid therapy.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service